Alpha Tau Medical (DRTS) CFO Raphi Levy Sells $220K of Stock

Inside Raphi Levy's Latest Stock Sale at Alpha Tau Medical

Alpha Tau Medical Ltd. (NasdaqCM: DRTS) Chief Financial Officer Raphi Levy continued his planned disposition of company shares, selling 20,000 shares on June 25, 2026. The shares changed hands at an average price of $11.00, bringing the total transaction value to $220,000. This follows a busy week of trading for the executive, who also parted with stock earlier in the month under pre-arranged guidelines.

Earlier Insider Transactions by the Chief Financial Officer

The June 25 trade built on a pair of identical transactions executed just days prior. On June 23, 2026, Levy sold 17,500 shares at an average price of $9.55, generating $167,049.75 in proceeds for each of those two separate filings. All three June sales by the chief financial officer were carried out under a pre-arranged Rule 10b5-1 trading plan, which allows corporate insiders to set up scheduled stock sales in advance without running afoul of insider trading rules.

Where DRTS Stock Trades Right Now

Shares of Alpha Tau Medical traded around $10.88 on Friday, sitting well above their 52-week low of $3.43 but below the 52-week high of $15.79. The biotechnology company carries a market capitalization of $1.40 billion. Because the company is still developing its medical treatments, it is not yet profitable, meaning it has no meaningful price-to-earnings ratio.

Analysts Set New Price Targets

Wall Street firms have kept a close eye on the clinical-stage oncology developer through the summer and fall. On September 3, 2026, Barclays maintained its Overweight rating on the stock while boosting its price target to $30.00 from $17.00. Earlier, on August 11, 2026, HC Wainwright & Co. kept a Buy rating while lifting its target to $16.00 from $15.00, following prior reiterations at a $15.00 target in July. Consensus analyst opinion sits at a Buy recommendation with a mean price target of $17.80.

What Alpha Tau Medical Works On

Alpha Tau Medical is based in Jerusalem, Israel, and focuses on developing diffusing alpha-emitters radiation therapy, known as Alpha DaRT, to treat solid tumors. The medical technology is currently moving through clinical trials targeting skin, oral, pancreatic, prostate, lung, liver, and breast cancers.

Looking Ahead for DRTS Investors

Investors tracking the biotechnology firm will want to mark their calendars for the company's next scheduled financial results report, which is expected on November 19, 2026. Insider transactions like those from the chief financial officer offer a window into executive portfolio management, though scheduled sales under pre-set plans are common corporate practice.